Earnings History Data for Inhibikase Therapeutics (IKT) - NYSE NASDAQ
To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.
For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.
For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.
See the full list of available companies here.
Inhibikase Therapeutics
Inhibikase Therapeutics Inc. is a clinical-stage pharmaceutical company. It engages in developing therapeutics for Parkinson's disease and related disorders. The company operates principally in Boston, Massachusetts. Inhibikase Therapeutics Inc. is headquartered in Atlanta, Georgia.
| Release Date | Time | Est. Time | Symbol | Name | Market Cap (M) | Rep. EPS | Est. EPS | Last years EPS | SeekingAlpha Headline | Price | Change | Ext. Hours Price | Ext. Hours Change | 52 Week Range | Volume | Avg. Volume | Ext. Hours Volume | Top Mover |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 27-03-2024 | AH | IKT | Inhibikase Therapeutics | 14.00 | -0.63 | -0.78 | 0.00 | Inhibikase Therapeutics GAAP EPS of -$3.57 misses by $0.82, revenue of $0.26M in-line [3/27/2024 4:44 PM] |
2.17 | -0.13 (-5.64%) |
2.20 | -0.10 (-4.35%) |
0.79 - 4.68 | 95,863 | 50,000 | 1,044 | ||
| 14-11-2023 | AH | IKT | Inhibikase Therapeutics, Inc. | 5.35 | -0.86 | -1.12 | -1.08 | Inhibikase Therapeutics GAAP EPS of -$0.86 [11/14/2023 4:35 PM] |
0.9210 | -0.06 (-6.02%) |
0.98 | 0.0 (0.00%) |
0.79 - 6.94 | 39,261 | 50,000 | 598 | ||
| 14-08-2023 | AH | IKT | Inhibikase Therapeutics, Inc. | 77.64 | -1.11 | -0.92 | -1.08 | Inhibikase Therapeutics GAAP EPS of -$1.11 misses by $0.19, revenue of $116.41M [8/14/2023 4:34 PM] |
2.40 | -0.09 (-3.61%) |
0.0 | 0.0 (0.00%) |
2.30 - 6.94 | 21,326 | 10,000 | 0 | ||
| 15-05-2023 | PM | After the close (May 15) |
IKT | Inhibikase Therapeutics, Inc. | 17.94 | -0.16 | -0.15 | -0.18 | Inhibikase Therapeutics GAAP EPS of -$0.16 misses by $0.01, revenue of $0.6M [5/15/2023 12:00 PM] |
0.6511 | -0.01 (-1.35%) |
0.69 | 0.03 (4.55%) |
0.44 - 1.21 | 88,731 | 100,000 | 23,442 | |
| 14-11-2022 | PM | After the close (Nov 14) |
IKT | Inhibikase Therapeutics, Inc. | 12.11 | -0.18 | 0.00 | -0.18 | Inhibikase Therapeutics GAAP EPS of -$0.18, revenue of $0.01M [11/15/2022 9:02 AM] |
0.6133 | 0.07 (13.03%) |
0.54 | 0.0 (-0.48%) |
0.44 - 2.34 | 370,482 | 320,000 | 2,000 | |
| 12-08-2022 | AH | After the close (Aug 12) |
IKT | Inhibikase Therapeutics, Inc. | 22.95 | -0.18 | 0.00 | -0.22 | Inhibikase Therapeutics GAAP EPS of -$0.18, revenue of $6.55M [8/12/2022 4:58 PM] |
0.7991 | -0.13 (-13.64%) |
0.89 | -0.04 (-3.81%) |
0.60 - 2.54 | 476,039 | 300,000 | 5,636 | |
| 16-05-2022 | AH | After the close (May 16) |
IKT | Inhibikase Therapeutics, Inc. | 17.25 | -0.18 | 0.00 | -0.26 | Inhibikase Therapeutics GAAP EPS of -$0.18, revenue of $0.05M [5/16/2022 5:07 PM] |
0.73 | 0.03 (4.49%) |
0.70 | 0.0 (0.20%) |
0.66 - 6.41 | 242,519 | 120,000 | 800 | |
| 31-03-2022 | AH | After the close (Mar 31) |
IKT | Inhibikase Therapeutics, Inc. | 33.99 | -0.20 | 0.00 | -0.15 | Inhibikase Therapeutics GAAP EPS of -$0.81, revenue of $3.1M [3/31/2022 5:02 PM] |
1.45 | -0.03 (-2.03%) |
1.49 | 0.01 (0.68%) |
0.90 - 6.96 | 35,148 | 80,000 | 500 | |